Advancing Our Initial Access Goals

We truly believe that through our capabilities and partnerships, serving patients in more than 165 countries and territories, we can contribute to progress on the sustainable development goal #3 - health and wellbeing for all.

Our Access Goals

Provide antiretroviral (ARV) therapy equivalent to a total of 30 million patients, including more than 2 million children living with HIV/AIDS, between 2022 and the end of 2025.

Impact 100 million patients via healthcare professional (HCP) education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025.

Our Progress

In 2022, we made progress toward our goal by providing treatments for approximately 8 million patients, including almost 600,000 children living with HIV/AIDS.

More than 19,000 individuals have an NCD Academy account, representing 48.6 million patients impacted.(1)

(1) Patient reach calculated by multiplying the number of HCP learners by the average number of patients treated, as self-reported by HCP learners upon registering for NCD Academy. Patient reach includes unique patients as well as repeat patient encounters. As of January 2023.

“We seek to understand the challenges faced by people and systems, and to co-create solutions that advance us collectively toward our shared objective of equitable, sustainable access. There are no easy fixes. We are here to do the hard work, to bring forward our expertise as one part of the solution.”

Erika Satterwhite, Head of Global Policy, Viatris